Osteoboost
Osteoboost is the first and only FDA-cleared prescription wearable device specifically designed to treat osteopenia in postmenopausal women, filling a critical treatment gap for over 50 million Americans with low bone density. Named a TIME Best Invention of 2025, this breakthrough medical device delivers precise, calibrated vibration therapy directly to the spine and hips—the areas most vulnerable to osteoporotic fractures. In a gold-standard 12-month clinical trial at the University of Nebraska Medical Center, Osteoboost demonstrated remarkable results: 85% reduction in spine bone density loss, 83% reduction in bone strength loss, and 55% reduction in hip bone density loss—all with zero serious adverse events. The comfortable belt worn for just 30 minutes daily during normal activities like walking or cooking, uses NASA-inspired technology originally developed for astronauts. Cleared through FDA's De Novo pathway with Breakthrough Device designation, Osteoboost offers a drug-free alternative that patients describe as feeling like a gentle massage. Available by prescription for $995 (special launch price), includes free 1-year access to Wellen exercise program, 30-day money-back guarantee, and 1-year warranty. Currently shipping 8-12 weeks after order with free delivery from partner pharmacy.
Stay in the Loop
Get updates from Osteoboost
Get exclusive updates from Osteoboost
Be the first to know about company milestones, news, and opportunities.
🔒 No spam. Just real progress.
Contact Information
Ways to reach Osteoboost
Are you the owner of Osteoboost?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company